A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of KVD900 Followed by Crossover Sub-studies of KVD900 Formulations, and Food Effect in Healthy Male Volunteers
Latest Information Update: 22 Feb 2023
At a glance
- Drugs Sebetralstat (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man
- Sponsors KalVista Pharmaceuticals
- 16 Feb 2023 According to a KalVista Pharmaceuticals media release, data from this study will be presented at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27. All results will be shared as a poster presentation and Q&A on Sunday, February 26 from 9:45-10:45 a.m. CST in the Convention Center, Lobby Level, Hall 2.
- 05 Jul 2022 According to a KalVista Pharmaceuticals media release, data from the study was presented at the EAACI 2022 conference.
- 22 Mar 2022 According to a KalVista Pharmaceuticals media release, data from the study was published in Clinical & Experimental Allergy.